BRPI0909016A2 - anticorpos úteis para o tratamento do câncer - Google Patents

anticorpos úteis para o tratamento do câncer

Info

Publication number
BRPI0909016A2
BRPI0909016A2 BRPI0909016A BRPI0909016A BRPI0909016A2 BR PI0909016 A2 BRPI0909016 A2 BR PI0909016A2 BR PI0909016 A BRPI0909016 A BR PI0909016A BR PI0909016 A BRPI0909016 A BR PI0909016A BR PI0909016 A2 BRPI0909016 A2 BR PI0909016A2
Authority
BR
Brazil
Prior art keywords
cancer treatment
antibodies useful
antibodies
useful
cancer
Prior art date
Application number
BRPI0909016A
Other languages
English (en)
Inventor
Jean-François Haeuw
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of BRPI0909016A2 publication Critical patent/BRPI0909016A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0909016A 2008-04-11 2009-04-08 anticorpos úteis para o tratamento do câncer BRPI0909016A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0801985A FR2929946B1 (fr) 2008-04-11 2008-04-11 Nouveaux anticorps anti-cd151 et leur utilisation pour le traitement du cancer
PCT/FR2009/050612 WO2009136070A1 (fr) 2008-04-11 2009-04-08 Nouveaux anticorps utiles pour le traitement du cancer

Publications (1)

Publication Number Publication Date
BRPI0909016A2 true BRPI0909016A2 (pt) 2015-12-22

Family

ID=39645493

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0909016A BRPI0909016A2 (pt) 2008-04-11 2009-04-08 anticorpos úteis para o tratamento do câncer

Country Status (23)

Country Link
US (3) US8198413B2 (pt)
EP (1) EP2268671A1 (pt)
JP (1) JP2011517565A (pt)
KR (1) KR20110010708A (pt)
CN (1) CN102027014A (pt)
AR (1) AR071304A1 (pt)
AU (1) AU2009245587B2 (pt)
BR (1) BRPI0909016A2 (pt)
CA (1) CA2720904A1 (pt)
CL (1) CL2009000862A1 (pt)
CO (1) CO6311009A2 (pt)
FR (1) FR2929946B1 (pt)
GE (1) GEP20135826B (pt)
IL (1) IL208595A0 (pt)
MA (1) MA32288B1 (pt)
MX (1) MX2010011147A (pt)
NZ (1) NZ588887A (pt)
RU (1) RU2010145063A (pt)
SA (1) SA109300216B1 (pt)
TW (1) TW201002347A (pt)
UA (1) UA105630C2 (pt)
WO (1) WO2009136070A1 (pt)
ZA (1) ZA201007751B (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2907341B1 (fr) * 2006-10-18 2012-08-17 Pf Medicament Utilisation d'un anticorps anti-cd151 pour le traitement du cancer
FR2929519B1 (fr) * 2008-04-04 2010-04-23 Pf Medicament Utilisation d'un anticorps anti-cd151 pour le traitement precoce des cancers.
EP2308897A1 (en) * 2009-10-09 2011-04-13 Pierre Fabre Medicament Chimeric antibodies specific for CD151 and use thereof in the treatment of cancer
AU2012214274B2 (en) * 2011-02-11 2017-02-02 Research Corporation Technologies, Inc. CH2 domain template molecules derived from rational grafting of donor loops onto CH2 scaffolds
WO2012131680A2 (en) 2011-03-28 2012-10-04 Yeda Research And Development Co. Ltd. Compositions and methods for treating inflammation
FR3017936B1 (fr) 2014-02-21 2019-03-15 Thales Systeme de regulation thermique d'au moins un module electronique embarque a bord d'un aeronef
SMT202200118T1 (it) * 2015-11-03 2022-05-12 Janssen Biotech Inc Anticorpi che legano specificamente pd-1 e loro usi
ITUB20154769A1 (it) 2015-11-04 2017-05-04 Centro Di Riferimento Oncologico Cro Irccs Aviano Anticorpo monoclonale anti-BARF1
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies
CN115925952A (zh) 2018-03-13 2023-04-07 东莞凡恩世生物医药有限公司 抗叶酸受体1抗体及其用途
CA3115077A1 (en) * 2018-10-09 2020-04-16 Ibex Biosciences, Llc Antibodies directed to filamin-a and therapeutic uses thereof
WO2023235666A2 (en) * 2022-05-31 2023-12-07 Vanderbilt University Human antibodies to bordetella pertussis and uses therefor
CN114790240B (zh) * 2022-06-10 2023-06-06 郑州大学 SARS-CoV-2中和性单克隆抗体及应用
CN119306826B (zh) * 2023-07-11 2025-06-20 东莞市朋志生物科技有限公司 抗白介素-6抗体、检测白介素-6的试剂和试剂盒

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999066027A1 (en) * 1998-06-15 1999-12-23 The Research Foundation Of State University Of New York Monoclonal antibodies that recognize antigens associated with tumor metastasis
US20070054278A1 (en) * 2003-11-18 2007-03-08 Applera Corporation Polymorphisms in nucleic acid molecules encoding human enzyme proteins, methods of detection and uses thereof
US20080003605A1 (en) * 2006-05-24 2008-01-03 The University Of Chicago Microarray analysis of light chain variable gene expression and methods of use
FR2907341B1 (fr) * 2006-10-18 2012-08-17 Pf Medicament Utilisation d'un anticorps anti-cd151 pour le traitement du cancer

Also Published As

Publication number Publication date
IL208595A0 (en) 2010-12-30
ZA201007751B (en) 2011-08-31
GEP20135826B (en) 2013-05-27
US20100150902A1 (en) 2010-06-17
JP2011517565A (ja) 2011-06-16
AU2009245587B2 (en) 2014-11-27
SA109300216B1 (ar) 2013-04-20
RU2010145063A (ru) 2012-05-20
AU2009245587A1 (en) 2009-11-12
WO2009136070A1 (fr) 2009-11-12
FR2929946A1 (fr) 2009-10-16
US20120284810A1 (en) 2012-11-08
UA105630C2 (uk) 2014-06-10
CN102027014A (zh) 2011-04-20
KR20110010708A (ko) 2011-02-07
US8198413B2 (en) 2012-06-12
CO6311009A2 (es) 2011-08-22
AR071304A1 (es) 2010-06-09
CL2009000862A1 (es) 2009-08-14
MX2010011147A (es) 2011-10-10
TW201002347A (en) 2010-01-16
US20140193329A1 (en) 2014-07-10
EP2268671A1 (fr) 2011-01-05
CA2720904A1 (fr) 2009-11-12
NZ588887A (en) 2012-10-26
US8697855B2 (en) 2014-04-15
MA32288B1 (fr) 2011-05-02
FR2929946B1 (fr) 2010-05-28

Similar Documents

Publication Publication Date Title
BRPI0918178A2 (pt) anticorpos monoclonais para tratamento de câncer
BRPI0909016A2 (pt) anticorpos úteis para o tratamento do câncer
IL197217B (en) Novel anti-cd38 antibodies for the treatment of cancer
BRPI0917204A2 (pt) variantes estruturais de anticorpos para melhores características terapêuticas
IL243376A0 (en) Antagonist antibody against epha2 for the treatment of cancer
BRPI0810206A2 (pt) Método de tratar câncer
PT2340042E (pt) Métodos e composições para o tratamento de cancro
BRPI0808814A2 (pt) Anticorpos monoclonais para o tratamento do câncer
BRPI0811907A2 (pt) Anticorpos monoclonais contra claudina-18 para tratamento de câncer.
BRPI0921321A2 (pt) métodos para o tratamento de indwcções e tumores
BRPI1014262A2 (pt) anticorpos específicos para caderina-17
BRPI1013618A2 (pt) pirimidinas substituídas para o tratamento de câncer
PL3059246T3 (pl) Zmodyfikowany region stały przeciwciała
BRPI0907237A2 (pt) Anticorpo anti-cldn6
HRP20171011T1 (hr) ANTI-eMET ANTITIJELO
DK2121139T3 (da) Formulations for cancer treatment
BRPI0922884A2 (pt) compostos para tratamento de câncer
BRPI0914784A2 (pt) processamento de hidrocarbonetos usando radiação
BRPI0813670A2 (pt) Compostos para tratamento
BRPI1010874A8 (pt) composição para o tratamento de câncer de próstata
BRPI1007972A2 (pt) composições de combinação e métodos para o tratamento de câncer
BRPI0909164A2 (pt) método e composições para o tratamento de câncer
BRPI1007995A2 (pt) orto-aminoamidas para o tratamento de cãncer.
PT2552963E (pt) Anticorpos anti cxcr4 humanizados para o tratamento de cancro
BRPI0909633A2 (pt) anticorpos anti-tyrp1

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2384 DE 13-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.